pcrA protein from Streptococcus pneumoniae

ABSTRACT

The invention provides pcrA polypeptides and DNA (RNA) encoding pcrA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing pcrA polypeptides to screen for antibacterial compounds.

RELATED APPLICATIONS

This is a divisional of application Ser. No. 08/889,711, filed Jul. 8, 1997 now U.S. Pat. No. 5,858,718.

This application claims benefit of U.S. application Ser. No. 60/024,022, filed August 16, 1996.

FIELD OF THE INVENTION

This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, in these and in other regards, the invention relates to novel polynucleotides and polypeptides of the DNA helicases family, hereinafter referred to as "pcrA".

BACKGROUND OF THE INVENTION

The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid. Since its isolation more than 100 years ago, Streptococcus pneumoniae has been one of the more intensively studied microbes. For example, much of our early understanding that DNA is, in fact, the genetic material was predicated on the work of Griffith and of Avery, Macleod and McCarty using this microbe. Despite the vast amount of research with S. pneumoniae, many questions concerning the virulence of this microbe remain. It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics.

The frequency of Streptococcus pneumoniae infections has risen dramatically in the past 20 years. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate Streptococcus pneumoniae strains which are resistant to some or all of the standard antibiotics. This has created a demand for both new anti-microbial agents and diagnostic tests for this organism.

A sequence related to those of the present invention is Gene Bank Accession number for Staphylococcus aureus homolog is M63176. See also, Iordanescu,S. M. and Bargonetti,J., "Staphylococcus aureus chromosomal mutations that decrease efficiency of Rep utilization in replication of pT181 and related plasmids," J. Bacteriol. 171, 4501-4503 (1989); Iordanescu,S., "Characterization of the Staphylococcus aureus chromosomal gene pcrA, identified by mutations affecting plasmid pT181 replication," Mol. Gen. Genet. 241 (1-2), 185-192 (1993).

Clearly, there is a need for factors, such as the novel compounds of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists which can play a role in preventing, ameliorating or correcting infections, dysfunctions or diseases.

The polypeptides of the invention have amino acid sequence homology to a known Staphylococcus aureus pcrA protein.

SUMMARY OF THE INVENTION

It is an object of the invention to provide polypeptides that have been identified as novel pcrA polypeptides by homology between the amino acid sequence set out in Table 1 [SEQ ID NO: 2] and a known amino acid sequence or sequences of other proteins such as Staphylococcus aureus pcrA protein.

It is a further object of the invention to provide polynucleotides that encode pcrA polypeptides, particularly polynucleotides that encode the polypeptide herein designated pcrA.

In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding pcrA polypeptides comprising the sequence set out in Table 1 [SEQ ID NO: 1] which includes a full length gene, or a variant thereof.

In another particularly preferred embodiment of the invention there is a novel pcrA protein from Streptococcus pneumoniae comprising the amino acid sequence of Table 1 [SEQ ID NO:2], or a variant thereof.

In accordance with another aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Streptococcus pneumoniae 0100993 strain contained in the deposited strain.

A further aspect of the invention there are provided isolated nucleic acid molecules encoding pcrA, particularly Streptococcus pneumoniae pcrA, including mRNAs, cDNAs, genomic DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization. Among the particularly preferred embodiments of the invention are naturally occurring allelic variants of pcrA and polypeptides encoded thereby.

Another aspect of the invention there are provided novel polypeptides of Streptococcus pneumoniae referred to herein as pcrA as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

Among the particularly preferred embodiments of the invention are variants of pcrA polypeptide encoded by naturally occurring alleles of the pcrA gene.

In a preferred embodiment of the invention there are provided methods for producing the aforementioned pcrA polypeptides.

In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies.

In accordance with certain preferred embodiments of the invention, there are provided products, compositions and methods for assessing pcrA expression, treating disease, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, assaying genetic variation, and administering a pcrA polypeptide or polynucleotide to an organism to raise an immunological response against a bacteria, especially a Streptococcus pneumoniae bacteria.

In accordance with certain preferred embodiments of this and other aspects of the invention there are provided polynucleotides that hybridize to pcrA polynucleotide sequences, particularly under stringent conditions.

In certain preferred embodiments of the invention there are provided antibodies against pcrA polypeptides.

In other embodiments of the invention there are provided methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the invention comprising: contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction being associated with a second component capable of providing a detectable signal in response to the binding or interaction of the polypeptide or polynucleotide with the compound; and determining whether the compound binds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the polypeptide or polynucleotide.

In accordance with yet another aspect of the invention, there are provided pcrA agonists and antagonists, preferably bacteriostatic or bactericidal agonists and antagonists.

In a further aspect of the invention there are provided compositions comprising a pcrA polynucleotide or a pcrA polypeptide for administration to a cell or to a multicellular organism.

Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.

GLOSSARY

The following definitions are provided to facilitate understanding of certain terms used frequently herein. "Host cell" is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., SIAM J. Applied Math., 48: 1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S. F. et al., J. Molec. Biol. 215: 403-410 (1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, Md. 20894; Altschul, S., et al., J. Mol. Biol. 215: 403-410 (1990). As an illustration, by a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO: 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO: 1. In other words, to obtain a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. Analogously , by a polypeptide having an amino acid sequence having at least, for example, 95% identity to a reference amino acid sequence of SEQ ID NO:2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ ID NO: 2. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a reference amino acid sequence, up to 5% of the amino acid residues in the reference sequence may be deleted or substituted with another amino acid, or a number of amino acids up to 5% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

"Isolated" means altered "by the hand of man" from its natural state, i.e., if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide(s)" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotide(s)" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and triple-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded regions, or a mixture of single- and double-stranded regions. In addition, "polynucleotide" as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term "polynucleotide(s)" also includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term "polynucleotide(s)" as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including, for example, simple and complex cells. "Polynucleotide(s)" also embraces short polynucleotides often referred to as oligonucleotide(s).

"Polypeptide(s)" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds. "Polypeptide(s)" refers to both short chains, commonly referred to as peptides, oligopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene encoded amino acids. "Polypeptide(s)" include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill in the art. It will be appreciated that the same type of modification may be present in the same or varying degree at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains, and the amino or carboxyl termini. Modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins, such as arginylation, and ubiquitination. See, for instance, PROTEINS--STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993) and Wold, F., Posttranslational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York (1983); Seifter et al., Meth. Enzymol. 182:626-646 (1990) and Rattan et al., Protein Synthesis: Posttranslational Modifications and Aging, Ann. N.Y. Acad. Sci. 663: 48-62 (1992). Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.

"Variant(s)" as the term is used herein, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.

DESCRIPTION OF THE INVENTION

The invention relates to novel pcrA polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a novel pcrA of Streptococcus pneumoniae, which is related by amino acid sequence homology to Staphylococcus aureus pcrA polypeptide. The invention relates especially to pcrA having the nucleotide and amino acid sequences set out in Table 1 [SEQ ID NO: 1] and Table 1 [SEQ ID NO: 2] respectively, and to the pcrA nucleotide sequences of the DNA in the deposited strain and amino acid sequences encoded thereby.

                                      TABLE 1                                      __________________________________________________________________________     pcrA Polynucleotide and Polypeptide Sequences                                  __________________________________________________________________________        -                                                                           (A)                                                                              Sequences from Streptococcus pneumoniae pcrA                                    polynucleotide sequence [SEQ ID NO:1].                                      5'-ATGAACGCAT                                                                     - TATTAAATGG AATGAATGAC CGTCAGGCTG AGGCGGTGCA AACGACAGAA                       - GGTCCCTTGC TAATCATGGC AGGGGCTGGT TCTGGAAAGA CTCGTGTTTT                       - GACCCACCGT ATCGCTTATT TGATTGATGA AAAGCTGGTC AATCTTTGGA                       - TATTTTTGGC CATTACCTTT ACCAACAAGG CTGCGCGTGA GATGAAAGAG                       - CGTGCTTATA GCCTCAATCC AGCGACTCAG GACTGTCTGA TTGCGACCTT                       - CCACTCCATG TGTGTGCGTA TTTTGCGTCG CGATGCGGAC CATATTGGCT                       - ACAATCGTAA TTTTACAATT GTGGATCCTG GTGAACAGCG AACGCTCATG                       - AAACGTATTC TCAAACAGTT GAACTTGGAC CCTAAAAAAT GGAATGAACG                       - AACTATTTTG GGGACCATTT CCAATGCTAA GAATGATTTG ATTGATGATG                       - TTGCTTATGC TGCCCAAGCT GGCGATATGT ATACGCAAAT TGTGGCCCAG                       - TGTTATACAG CCTATCAAAA AGAACTTCGT CAGTCTGAAT CCGTTGACTT                       - TGATGATTTG ATTATGCTGA CCTTGCGTCT CTTTGATCAA AATCCTGATG                       - TTTTGACCTA CTACCAGCAA AAATTCCAAT ACATCCACGT TGATGAGTAC                       - CAAGATACCA ACCACGCTCA GTACCAATTG GTCAAACTCT TGGCTTCCCG                       - TTTTAAAAAT ATCTGTGTGG TTGGGGATGC GGACCAGTCT ATCTACGGTT                       - GGCGTGGTGC TGATATGCAG AATATCTTGG ACTTTGAAAA GGATTACCCC                       - AAAGCCAAGG TTGTTTTGTT GGAGGAAAAT TACCGCTCAA CCAAAACCAT                       - TCTCCAAGCG GCCAACGAGG TTATTAAAAA TAATAAAAAT CGCCGTCCTA                       - AAAATCTCTG GACTCAAAAC GCTGATGGGG AGCAAATCGT TTACTATCGT                       - GCCGATGATG AGCTGGATGA GGCTGTATTT GTAGCCAGAA CCATCGATGA                       - ACTTAGTCGC AGTCAAAACT TCCTTCATAA GGATTTTGCA GTTCTCTATC                       - GGACTAATGC CCAGTCCCGT ACAATTGAGG AAGCCCTGCT CAAGTCTAAC                       - ATTCCTTATA CCATGGTTGG CGGAACCAAA TTCTACAGCC GTAAGGAAAT                       - TCGCGATATT ATTGCTTATC TCATCTTTAT TGCTAATTTG AGTGACAATA                       - TTAGTTTTGA GCGTATTATC AACGAGCCTA AACGTGGAAT TGGTCTAGGT                       - ACAGTTGAGA AAATCCGTGA TTTTGCAAAT TTGCAAAATA TGTCTATGCT                       - GGATGCTTCT GCTAATATTA TGTTGTCTGG TATCAAGGGT AAGGCAGCCC                       - AATCTATCTG GGATTTTGCC AATATGATGC TTGATTTGCG GGAGCAGCTA                       - GACCACTTAA GCATTACAGA GTTGGTTGAG TCCGTCCTAG AAAAAACAGG                       - TTATGTCGAT ATTCTTAACG CCCAAGCGAC TCTAGAAAGC AAGGCACGGG                       - TTGAAAATAT CGAAGAGTTT CTTTCTGTTA CGAAGAACTT TGATGACACC                       - ACGGATGTGA CAGAAGAGGA AACTGGTCTG GACAAACTGA GTCGTTTCTT                       - AAATGACTTG GCTTTGATTG CCGACACAGA TTCAGGTAGT CAGGAGACAT                       - CAGAAGTGAC CTTGATGACC CTGCATGCTG CCAAAGGTCT CGAATTTCCA                       - GTTGTCTTTT TGATTGGGAT GGAAGAAAAT GTCTTTCCAC TTAGTCGTGC                       - GACTGAAGAT TCAGATGAAT TAGAAGAAGA GCGCCGTCTA GCCTATGTAG                       - GTATCACGCG TGCAGAGAAA ATTCTCTATC TGACCAATGC CAACTCACGC                       - TTGCTTTTTG GTCGTACCAA TTATAACCGT CCGACTCGTT TTATTAACGA                       - AATCAGTTCA GACTTGCTTG AGTATCAAGG TCTGGCTCGT CCTGCAAATA                       - CAAGCTTTAA GGCATCATAT AGCAGTGGTA GTATTTCCTT TGGTCAAGGT                       - ATGAGTTTGG CTCAGGCTCT TCAAGACCGT AAACGCGGTG CTGCCCCAAA                       - ATCAATCCAG TCAAGCGGTC TTCCATTTGG TCAATTTACA GCTGGCGCAA                       - AACCAGCATC TAGCGAGGCA AATTGGTCCA TTGGTGATAT TGCTCTCCAC                       - AAGAAATGGG GAGAGGGAAC CGTTCTGGAA GTTTCAGGTA GCGGTGCTAG                       - GCAGGAATTG AAAATCAATT TCCCAGAAGT AGGTTTGAAA AAACTTTTAG                       - CCAGTGTGGC TCCAATTGAG AAAAAAATCT AA                                        3'                                                                               -                                                                           (B)                                                                              pcrA polypeptide sequence deduced from the polynucleotide                       sequence in this table [SEQ ID NO:2].                                       NH.sub.2 -MNALLNGMND RQAEAVQTTE GPLLIMAGAG SGKTRVLTHR IAYLIDEKLV                  - NLWIFLAITF ThKAAREMKE RAYSLNPATQ DCLIATFHSM CVRILRRDAD                       - HIGYNRNFTI VDPGEQRTLM KRILKQLNLD PKKWNERTIL GTISNAKNDL                       - IDDVAYAAQA GDMYTQIVAQ CYTAYQKEtR QSESVDFDDL IMLTLRLFDQ                       - NPDVLTYYQQ KFQYIHVDEY QDTNHAQYQL VKLLASRFKN ICVVGDADQS                       - IYGWRGADMQ NILDFEKDYP KAKVVLLEEN YRSTKTILQA ANEVIKNNKN                       - RRPKNLWTQN ADGEQIVYYR ADDELDEAVF VARTIDELSR SQNFLHKDFA                       - VLYRTNAQSR TIEEALLKSN IPYTMVGGTK FYSRKEIRDI IAYLIFIANL                       - SDNISFERII NEPKRGIGLG TVEKIRDFAN LQNMSMLDAS ANIMLSGIKG                       - KAAQSIWDFA NMMLDLREQL DHLSITELVE SVLEKTGYVD ILNAQATLES                       - KARVENIEEF LSVTKNFDDT TDVTEEETGL DKLSRFLNDL ALIADTDSGS                       - QETSEVTLMT LHAAKGLEFP VVFLIGMEEN VFPLSRATED SDELEEERRL                       - AYVGITRAEK ILYLThANSR LLFGRTNYNR PTRFINEISS DLLEYQGLAR                       - PANTSFKASY SSGSISFGQG MSLAQALQDR KRGAAPKSIQ SSGLPFGQFT                       - AGAKPASSEA NWSIGDIALH KKWGEGTVLE VSGSGARQEL KINFPEVGLK                       - KLLASVAPIE KKI                                                               - -COOH                                                                        -                                                                           (C)                                                                              Polynucleotide sequence embodiments [SEQ ID NO: 1].                          X-(R.sub.1).sub.n)l -ATGAACGCAT                                                   - TATTAAATGG AATGAATGAC CGTCAGGCTG AGGCGGTGCA AACGACAGAA                       - GGTCCCTTGC TAATCATGGC AGGGGCTGGT TCTGGAAAGA CTCGTGTTTT                       - GACCCACCGT ATCGCTTATT TGATTGATGA AAAGCTGGTC AATCTTTGGA                       - TATTTTTGGC CATTACCTTT ACCAACAAGG CTGCGCGTGA GATGAAAGAG                       - CGTGCTTATA GCCTCAATCC AGCGACTCAG GACTGTCTGA TTGCGACCTT                       - CCACTCCATG TGTGTGCGTA TTTTGCGTCG CGATGCGGAC CATATTGGCT                       - ACAATCGTAA TTTTACAATT GTGGATCCTG GTGAACAGCG AACGCTCATG                       - AAACGTATTC TCAAACAGTT GAACTTGGAC CCTAAAAAAT GGAATGAACG                       - AACTATTTTG GGGACCATTT CCAATGCTAA GAATGATTTG ATTGATGATG                       - TTGCTTATGC TGCCCAAGCT GGCGATATGT ATACGCAAAT TGTGGCCCAG                       - TGTTATACAG CCTATCAAAA AGAACTTCGT CAGTCTGAAT CCGTTGACTT                       - TGATGATTTG ATTATGCTGA CCTTGCGTCT CTTTGATCAA AATCCTGATG                       - TTTTGACCTA CTACCAGCAA AAATTCCAAT ACATCCACGT TGATGAGTAC                       - CAAGATACCA ACCACGCTCA GTACCAATTG GTCAAACTCT TGGCTTCCCG                       - TTTTAAAAAT ATCTGTGTGG TTGGGGATGC GGACCAGTCT ATCTACGGTT                       - GGCGTGGTGC TGATATGCAG AATATCTTGG ACTTTGAAAA GGATTACCCC                       - AAAGCCAAGG TTGTTTTGTT GGAGGAAAAT TACCGCTCAA CCAAAACCAT                       - TCTCCAAGCG GCCAACGAGG TTATTAAAAA TAATAAAAAT CGCCGTCCTA                       - AAAATCTCTG GACTCAAAAC GCTGATGGGG AGCAAATCGT TTACTATCGT                       - GCCGATGATG AGCTGGATGA GGCTGTATTT GTAGCCAGAA CCATCGATGA                       - ACTTAGTCGC AGTCAAAACT TCCTTCATAA GGATTTTGCA GTTCTCTATC                       - GGACTAATGC CCAGTCCCGT ACAATTGAGG AAGCCCTGCT CAAGTCTAAC                       - ATTCCTTATA CCATGGTTGG CGGAACCAAA TTCTACAGCC GTAAGGAAAT                       - TCGCGATATT ATTGCTTATC TCATCTTTAT TGCTAATTTG AGTGACAATA                       - TTAGTTTTGA GCGTATTATC AACGAGCCTA AACGTGGAAT TGGTCTAGGT                       - ACAGTTGAGA AAATCCGTGA TTTTGCAAAT TTGCAAAATA TGTCTATGCT                       - GGATGCTTCT GCTAATATTA TGTTGTCTGG TATCAAGGGT AAGGCAGCCC                       - AATCTATCTG GGATTTTGCC AATATGATGC TTGATTTGCG GGAGCAGCTA                       - GACCACTTAA GCATTACAGA GTTGGTTGAG TCCGTCCTAG AAAAAACAGG                       - TTATGTCGAT ATTCTTAACG CCCAAGCGAC TCTAGAAAGC AAGGCACGGG                       - TTGAAAATAT CGAAGAGTTT CTTTCTGTTA CGAAGAACTT TGATGACACC                       - ACGGATGTGA CAGAAGAGGA AACTGGTCTG GACAAACTGA GTCGTTTCTT                       - AAATGACTTG GCTTTGATTG CCGACACAGA TTCAGGTAGT CAGGAGACAT                       - CAGAAGTGAC CTTGATGACC CTGCATGCTG CCAAAGGTCT CGAATTTCCA                       - GTTGTCTTTT TGATTGGGAT GGAAGAAAAT GTCTTTCCAC TTAGTCGTGC                       - GACTGAAGAT TCAGATGAAT TAGAAGAAGA GCGCCGTCTA GCCTATGTAG                       - GTATCACGCG TGCAGAGAAA ATTCTCTATC TGACCAATGC CAACTCACGC                       - TTGCTTTTTG GTCGTACCAA TTATAACCGT CCGACTCGTT TTATTAACGA                       - AATCAGTTCA GACTTGCTTG AGTATCAAGG TCTGGCTCGT CCTGCAAATA                       - CAAGCTTTAA GGCATCATAT AGCAGTGGTA GTATTTCCTT TGGTCAAGGT                       - ATGAGTTTGG CTCAGGCTCT TCAAGACCGT AAACGCGGTG CTGCCCCAAA                       - ATCAATCCAG TCAAGCGGTC TTCCATTTGG TCAATTTACA GCTGGCGCAA                       - AACCAGCATC TAGCGAGGCA AATTGGTCCA TTGGTGATAT TGCTCTCCAC                       - AAGAAATGGG GAGAGGGAAC CGTTCTGGAA GTTTCAGGTA GCGGTGCTAG                       - GCAGGAATTG AAAATCAATT TCCCAGAAGT AGGTTTGAAA AAACTTTTAG                       - CCAGTGTGGC TCCAATTGAG AAAAAAATCT AA                                          - -(R.sub.2).sub.n - y                                                         -                                                                           (D)                                                                              Polypeptide sequence embodiments [SEQ ID NQ:2].                              X-(R.sub.1).sub.n -MNALLNGMND RQAEAVQTTE GPLLIMAGAG SGKTRVLTHR IAYLIDEKLV        - NLWIFLAITF ThKAAREMKE RAYSLNPATQ DCLIATFHSM CVRILRRDAD                       - HIGYNRNFTI VDPGEQRTLM KRILKQLNLD PKKWNERTIL GTISNAKNDL                       - IDDVAYAAQA GDMYTQIVAQ CYTAYQKELR QSESVDFDDL IMLTLRLFDQ                       - NPDVLTYYQQ KFQYIHVDEY QDTNHAQYQL VKLLASRFKN ICVVGDADQS                       - IYGWRGADMQ NILDFEKDYP KAKVVLLEEN YRSTKTILQA ANEVIKNNKN                       - RRPKNLWTQN ADGEQIVYYR ADDELDEAVF VARTIDELSR SQNFLHKDFA                       - VLYRTNAQSR TIEEALLKSN IPYTMVGGTW FYSRKEIRDI IAYLIFIANL                       - SDNISFERII NEPKRGIGLG TVEKIRDFAN LQNMSMLDAS ANIMLSGIKG                       - KAAQSIWDFA NMMLDLREQL DHLSITELVE SVLEKTGYVD ILNAQATLES                       - KARVENIEEF LSVTKWFDDT TDVTEEETGL DKLSRFLNDL ALIADTDSGS                       - QETSEVTLMT LHAAKGLEFP VVFLIGMEEN VFPLSRATED SDELEEERRL                       - AYVGITRAEK ILYLThANSR LLFGRTNYNR PTRFINEISS DLLEYQGLAR                       - PANTSFKASY SSGSISFGQG MSLAQALQDR KRGAAPKSIQ SSGLPFGQFT                       - AGAKPASSEA NWSIGDIALH KKWGEGTVLE VSGSGARQEL KINFPEVGLK                       - KLLASVAPIE KKI                                                               - -(R.sub.2).sub.n -Y                                                          -                                                                            (E)                                                                              Sequences from Streptococcus pneumoniae pcrA                                    polynucleotide ORF sequence [SEQ ID NO:3].                                  5'-1 CTACAACTCT TGGTTACTAA GCGCTTCAAC TCCTTCCTTG GCCAGCCTTT                       -                                                                             51                                                                              CTCTTGGTAA TAGTGAATCT TCTTGGAATG AAATACTGTA CATAAAAATC                         -  101CTCCTCACTT TATTATTCGT GAGAAGGATG GAAAATTAGA TTTTTTTCTC                   -  151AATTGGAGCC ACACTGGCTA AAAGTTTTTT CAAACCTACT TCTGGGAAAT                   -  201TGATTTTCAA TTCCTGCCTA GCACCGCTAC CTGAAACTTC CAGAACGGTT                   -  251CCCTCTCCCC ATTTCTTGTG GAGAGCAATA TCACCAATGG ACCAATTTGC                   -  301CTCGCTAGAT GCTGGTTTTG CGCCAGCTGT AAATTGACCA AATGGAAGAC                   -  351CGCTTGACTG GATTGATTTT GGGGCAGCAC CGCGTTTACG GTCTTGAAGA                   -  401GCCTGAGCCA AACTCATACC TTGACCAAAG GAAATACTAC CACTGCTATA                   -  451TGATGCCTTA AAGCTTGTAT TTGCAGGACG AGCCAGACCT TGATACTCAA                   -  501GCAAGTCTGA ACTGATTTCG TTAATAAAAC GAGTCGGACG GTTATAATTG                   -  551GTACGACCAA AAAGCAAGCG TGAGTTGGCA TTGGTCAGAT AGAGAATTTT                   -  601CTCTGCACGC GTGATACCTA CATAGGCTAG ACGGCGCTCT TCTTCTAATT                   -  651CATCTGAATC TTCAGTCGCA CGACTAAGTG GAAAGACATT TTCTTCCATC                   -  701CCAATCAAAA AGACAACTGG AAATTCGAGA CCTTTGGCAG CATGCAGGGT                   -  751CATCAAGGTC ACTTCTGATG TCTCCTGACT ACCTGAATCT GTGTCGGCAA                   -  801TCAAAGCCAA GTCATTTAAG AAACGACTCA GTTTGTCCAG ACCAGTTTCC                   -  851TCTTCTGTCA CATCCGTGGT GTCATCAAAG TTCTTCGTAA CAGAAAGAAA                   -  901CTCTTCGATA TTTTCAACCC GTGCCTTGCT TTCTAGAGTC GCTTGGGCGT                   -  951TAAGAATATC GACATAACCT GTTTTTTCTA GGACGGACTC AACCAACTCT                   - 1001GTAATGCTTA AGTGGTCTAG CTGCTCCCGC AAATCAAGCA TCATATTGGC                   - 1051AAAATCCCAG ATAGATTGGG CTGCCTTACC CTTGATACCA GACAACATAA                   - 1101TATTAGCAGA AGCATCCAGC ATAGACATAT TTTGCAAATT TGCAAAATCA                   - 1151CGGATTTTCT CAACTGTACC TAGACCAATT CCACGTTTAG GCTCGTTGAT                   - 1201AATACGCTCA AAACTAATAT TGTCACTCAA ATTAGCAATA AGGTTGAGAT                   - 1251AAGCAATAAT ATCGCGAATT TCCTTACGGC TGTAGAATTT GGTTCCGCCA                   - 1301ACCATGGTAT AAGGAATGTT AGACTTGAGC AGGGCTTCAT CGAATTGTAC                   - 1351GGGACTGGGC ATTAGTCCGA TAGAGAACTG CAAAATCCTT ATGAAGGAAG                   - 1401TTTTGACTGC GACTAAGTTC ATCGATGGTT CTGGCTACAA ATACAGCCTC                   - 1451ATCCAGCTCA TCATCGGCAC GATAGTAAAC GATTTGCTCC CCATCAGCGT                   - 1501TTTGAGTCCA GAGATTTTTA GGACGGCGAT TTTTATTATT TTTAATAACC                   - 1551TCGTTGGCCG CTTGGAGAAT GGTTTTGGTT GAGC                                  3'                                                                               -                                                                           (F)                                                                               pcrApolypeptide sequence deduced from the                                      polynucleotide ORF sequence in this table                                      [SEQ ID NQ:4].                                                              NH.sub.2 -1 MNLVAVKTSF IRILQFSIGL MPSPVQFDEA LLKSNIPYTM VGGTKFYSRK               -                                                                              51                                                                              EIRDIIAYLN LIANLSDNIS FERIINEPKR GIGLGTVEKI RDFANLQNMS                         -  101MLDASANIML SGIKGKAAQS IWDFANMMLD LREQLDHLSI TELVESVLEK                   -  151TGYVDILNAQ ATLESKARVE NIEEFLSVTK NFDDTTDVTE EETGLDKLSR                   -  201FLNDLALIAD TDSGSQETSE VTLMTLHAAK GLEFPVVFLI GMEENVFPLS                   -  251RATEDSDELE EERRLAYVGI TRAEKILYLT NANSRLLFGR TNYNRPTRFI                   -  301NEISSDLLEY QGLARPANTS FKASYSSGSI SFGQGMSLAQ ALQDRKRGAA                   -  351PKSIQSSGLP FGQFTAGAKP ASSEANWSIG DIALHKKWGE GTVLEVSGSG                   -  401ARQELKINFP EVGLKKLLAS VAPIEKKI-COOH                                   __________________________________________________________________________

Deposited materials

A deposit containing a Streptococcus pneumoniae 0100993 strain has been deposited with the National Collections of Industrial and Marine Bacteria Ltd. (herein "NCIMB"), 23 St. Machar Drive, Aberdeen AB2 IRY, Scotland on Apr. 11, 1996 and assigned deposit number 40794. The deposit was described as Streptococcus peumnoiae 0100993 on deposit. On Apr. 17, 1996 a Streptococcus pneumoniae 0100993 DNA library in E. coli was similarly depositedwith the NCIMB and assigned deposit number 40800. The Streptococcus pneumoniae strain deposit is referred to herein as "the deposited strain" or as "the DNA of the deposited strain."

The deposited strain contains the full length pcrA gene. The sequence of the polynucleotides contained in the deposited strain, as well as the amino acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any description of sequences herein.

The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The strain will be irrevocably and without restriction or condition released to the public upon the issuance of a patent. The deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. § 112.

A license may be required to make, use or sell the deposited strain, and compounds derived therefrom, and no such license is hereby granted.

Polypeptides

The polypeptides of the invention include the polypeptide of Table 1 [SEQ ID NO:2] (in particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of pcrA, and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ID NOS:2 and 4] or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NOS:2 and 4], and more preferably at least 90% similarity (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NOS:2 and 4] and still more preferably at least 95% similarity (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ID NOS:2 and 4] and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 amino acids and more preferably at least 50 amino acids.

The invention also includes polypeptides of the formula set forth in Table 1 (D) [SEQ ID NO:2] wherein, at the amino terminus, X is hydrogen, and at the carboxyl terminus, Y is hydrogen or a metal, R₁ and R₂ is any amino acid residue, and n is an integer between 1 and 1000. Any stretch of amino acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

A fragment is a variant polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the aforementioned polypeptides. As with pcrA polypeptides fragments may be "free-standing," or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region, a single larger polypeptide.

Preferred fragments include, for example, truncation polypeptides having a portion of an amino acid sequence of Table 1 [SEQ ID NOS:2 and 4], or of variants thereof, such as a continuous series of residues that includes the amino terminus, or a continuous series of residues that includes the carboxyl terminus. Degradation forms of the polypeptides of the invention in a host cell, particularly a Streptococcus pneumoniae, are also preferred. Further preferred are fragments characterized by structural or functional attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

Also preferred are biologically active fragments which are those fragments that mediate activities of pcrA, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those fragments that are antigenic or immunogenic in an animal, especially in a human. Particularly preferred are fragments comprising receptors or domains of enzymes that confer a function essential for viability of Streptococcus pneumoniae or the ability to initiate, or maintain cause disease in an individual, particularly a human.

Variants that are fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these variants may be employed as intermediates for producing the full-length polypeptides of the invention.

Polynucleotides

Another aspect of the invention relates to isolated polynucleotides, including the full length gene, that encode the pcrA polypeptide having a deduced amino acid sequence of Table 1 [SEQ ID NOS:2 and 4] and polynucleotides closely related thereto and variants thereof.

Using the information provided herein, such as a polynucleotide sequence set out in Table 1 [SEQ ID NOS: 1 and 3], a polynucleotide of the invention encoding pcrA polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using Streptococcus pneumoniae 0100993 cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as a sequence given in Table 1 [SEQ ID NOS: 1 and 3], typically a library of clones of chromosomal DNA of Streptococcus pneumoniae 0100993 in E. coli or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 7-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent conditions. By sequencing the individual clones thus identified with sequencing primers designed from the original sequence it is then possible to extend the sequence in both directions to determine the full gene sequence. Conveniently, such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E. F. and Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Illustrative of the invention, the polynucleotide set out in Table 1 [SEQ ID NO:1] was discovered in a DNA library derived from Streptococcus pneumoniae 0100993.

The DNA sequence set out in Table 1 [SEQ ID NOS:1] contains an open reading frame encoding a protein having about the number of amino acid residues set forth in Table 1 [SEQ ID NO:2] with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known in the art. The polynucleotide of SEQ ID NO: 1, between nucleotide number 1 through number 2289 encodes the polypeptide of SEQ ID NO:2. The stop codon begins at nucleotide number 2290 of SEQ ID NO: 1.12289.

The pcrA protein of the invention is structurally related to other proteins of the DNA helicases family, as shown by the results of sequencing the DNA encoding pcrA of the deposited strain. The protein exhibits greatest homology to Staphylococcus aureus pcrA protein among known proteins. pcrA of Table 1 [SEQ ID NO:2] has about 57%% identity over its entire length with the amino acid sequence of Staphylococcus aureus pcrA polypeptide.

The invention provides a polynucleotide sequence identical over its entire length to the coding sequence in Table 1 [SEQ ID NO: 1]. Also provided by the invention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment in reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence. The polynucleotide may also contain non-coding sequences, including for example, but not limited to non-coding 5' and 3' sequences, such as the transcribed, non-translated sequences, termination signals, ribosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and additional coding sequence which encode additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz et al., Proc. Natl. Acad. Sci., USA 86: 821-824 (1989), or an HA tag (Wilson et al., Cell 37. 767 (1984). Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.

A preferred embodiment of the invention is a polynucleotide of comprising nucleotide 1 to 2289 or 2290 set forth in SEQ ID NO: 1 of Table 1 which encode the pcrA polypeptide.

The invention also includes polynucleotides of the formula set forth in Table 1 (C)[SEQ ID NO: 1] wherein, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal, R₁ and R₂ is any nucleic acid residue, and n is an integer between 1 and 1000. Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.

The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the Streptococcus pneumoniae pcrA having the amino acid sequence set out in Table 1 [SEQ ID NO:2]. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, interrupted by integrated phage or an insertion sequence or editing) together with additional regions, that also may contain coding and/or non-coding sequences.

The invention further relates to variants of the polynucleotides described herein that encode for variants of the polypeptide having the deduced amino acid sequence of Table 1 [SEQ ID NO:2]. Variants that are fragments of the polynucleotides of the invention may be used to synthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding pcrA variants, that have the amino acid sequence of pcrA polypeptide of Table 1 [SEQ ID NO:2] in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of pcrA.

Further preferred embodiments of the invention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding pcrA polypeptide having an amino acid sequence set out in Table 1 [SEQ ID NOS:2 and 4], and polynucleotides that are complementary to such polynucleotides. Alternatively, most highly preferred are polynucleotides that comprise a region that is at least 80% identical over its entire length to a polynucleotide encoding pcrA polypeptide of the deposited strain and polynucleotides complementary thereto. In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

Preferred embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Table 1 [SEQ ID NO: 1].

The invention further relates to polynucleotides that hybridize to the herein above-described sequences. In this regard, the invention especially relates to polynucleotides that hybridize under stringent conditions to the herein above-described polynucleotides. As herein used, the terms "stringent conditions" and "stringent hybridization conditions" mean hybridization will occur only if there is at least 95% and preferably at least 97% identity between the sequences. An example of stringent hybridization conditions is overnight incubation at 42° C. in a solution comprising: 50% formamide, 5× SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5× Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1× SSC at about 65° C. Hybridization and wash conditions are well known and exemplified in Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein.

The invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO: 1 or SEQ ID NO:3 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO: 1 or a fragment thereof; and isolating said DNA sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers described elsewhere herein.

As discussed additionally herein regarding polynucleotide assays of the invention, for instance, polynucleotides of the invention as discussed above, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding pcrA and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the pcrA gene. Such probes generally will comprise at least 15 bases. Preferably, such probes will have at least 30 bases and may have at least 50 bases. Particularly preferred probes will have at least 30 bases and will have 50 bases or less.

For example, the coding region of the pcrA gene may be isolated by screening using the DNA sequence provided in SEQ ID NO: 1 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or MRNA to determine which members of the library the probe hybridizes to.

The polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and materials for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to polynucleotide assays.

Polynucleotides of the invention that are oligonucleotides derived from the sequences of SEQ ID NOS: 1 and/or 2 may be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.

The invention also provides polynucleotides that may encode a polypeptide that is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case in vivo, the additional amino acids may be processed away from the mature protein by cellular enzymes.

A precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

Vectors, host cells, expression

The invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis et al., BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook et al., MOLECULAR CLONING. A LABORATORY MANUAL, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction and infection.

Representative examples of appropriate hosts include bacterial cells, such as streptococci, staphylococci, enterococci E. coli, streptomyces and Bacillus subtilis cells; fungal cells, such as yeast cells and Aspergillus cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used to produce the polypeptides of the invention. Such vectors include, among others, chromosomal, episomal and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL, (supra).

For secretion of the translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.

Polypeptides of the invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

Diagnostic Assays

This invention is also related to the use of the pcrA polynucleotides of the invention for use as diagnostic reagents. Detection of pcrA in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease. Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, infected with an organism comprising the pcrA gene may be detected at the nucleic acid level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification technique prior to analysis. RNA or cDNA may also be used in the same ways. Using amplification, characterization of the species and strain of prokaryote present in an individual, may be made by an analysis of the genotype of the prokaryote gene. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the genotype of a reference sequence. Point mutations can be identified by hybridizing amplified DNA to labeled pcrA polynucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing. See, e.g., Myers et al., Science, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and S1 protection or a chemical cleavage method. See, e.g., Cotton et al., Proc. Natl. Acad. Sci., USA, 85: 4397-4401 (1985).

Cells carrying mutations or polymorphisms in the gene of the invention may also be detected at the DNA level by a variety of techniques, to allow for serotyping, for example. For example, RT-PCR can be used to detect mutations. It is particularly preferred to used RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan. RNA or cDNA may also be used for the same purpose, PCR or RT-PCR. As an example, PCR primers complementary to a nucleic acid encoding pcrA can be used to identify and analyze mutations.

The invention further provides these primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. These primers may be used for, among other things, amplifying pcrA DNA isolated from a sample derived from an individual. The primers may be used to amplify the gene isolated from an infected individual such that the gene may then be subject to various techniques for elucidation of the DNA sequence. In this way, mutations in the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent.

The invention further provides a process for diagnosing, disease, preferably bacterial infections, more preferably infections by Streptococcus pneumoniae, and most preferably otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, comprising determining from a sample derived from an individual a increased level of expression of polynucleotide having the sequence of Table 1 [SEQ ID NO: 1]. Increased or decreased expression of pcrA polynucleotide can be measured using any on of the methods well known in the art for the quantation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods.

In addition, a diagnostic assay in accordance with the invention for detecting over-expression of pcrA protein compared to normal control tissue samples may be used to detect the presence of an infection, for example. Assay techniques that can be used to determine levels of a pcrA protein, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Antibodies

The polypeptides of the invention or variants thereof, or cells expressing them can be used as an immunogen to produce antibodies immunospecific for such polypeptides. "Antibodies" as used herein includes monoclonal and polyclonal antibodies, chimeric, single chain, simianized antibodies and humanized antibodies, as well as Fab fragments, including the products of an Fab immunolglobulin expression library.

Antibodies generated against the polypeptides of the invention can be obtained by administering the polypeptides or epitope-bearing fragments, analogues or cells to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique known in the art that provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., Nature 256: 495497 (1975); Kozbor et al., Immunology Today 4: 72 (1983); Cole et al., pg. 77-96 in MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc. (1985).

Techniques for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies.

Alternatively phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-pcrA or from naive libraries (McCafferty, J. et al., (1990), Nature 348, 552-554; Marks, J. et al., (1992) Biotechnology 10, 779-783). The affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al., (1991) Nature 352, 624-628).

If two antigen binding domains are present each domain may be directed against a different epitope--termed `bispecific` antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides to purify the polypeptides by affinity chromatography.

Thus, among others, antibodies against pcrA-polypeptide may be employed to treat infections, particularly bacterial infections and especially otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid.

Polypeptide variants include antigenically, epitopically or immunologically equivalent variants that form a particular aspect of this invention. The term "antigenically equivalent derivative" as used herein encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host. The term "immunologically equivalent derivative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host.

The polypeptide, such as an antigenically or immunologically equivalent derivative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken. The fusion protein may provide stability to the polypeptide. The antigen may be associated, for example by conjugation, with an immunogenic carrier protein for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH). Alternatively a multiple antigenic peptide comprising multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.

Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized"; where the complimentarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody , for example as described in Jones, P. et al. (1986), Nature 321, 522-525 or Tempest et al., (1991) Biotechnology 9, 266-273.

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al., Hum Mol Genet 1992, 1:363, Manthorpe et al., Hum. Gene Ther. 1963:4, 419), delivery of DNA complexed with specific protein carriers (Wu et al., J Biol Chem. 1989: 264,16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, PNAS USA, 1986:83,9551), encapsulation of DNA in various forms of liposomes (Kaneda et al., Science 1989:243,375), particle bombardment (Tang et al., Nature 1992, 356:152, Eisenbraun et al., DNA Cell Biol 1993, 12:791) and in vivo infection using cloned retroviral vectors (Seeger et al., PNAS USA 1984:81,5849).

Antagonists and agonists--assays and molecules

Polypeptides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, e.g., Coligan et al., Current Protocols in Immunology 1(2). Chapter 5 (1991).

The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of pcrA polypeptides or polynucleotides, particularly those compounds that are bacteriostatic and/or bactericidal. The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagoists, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising pcrA polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a pcrA agonist or antagonist. The ability of the candidate molecule to agonize or antagonize the pcrA polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously, i.e., without inducing the effects of pcrA polypeptide are most likely to be good antagonists. Molecules that bind well and increase the rate of product production from substrate are agonists. Detection of the rate or level of production of product from substrate may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colorimetric labeled substrate converted into product, a reporter gene that is responsive to changes in pcrA polynucleotide or polypeptide activity, and binding assays known in the art.

Another example of an assay for pcrA antagonists is a competitive assay that combines pcrA and a potential antagonist with pcrA-binding molecules, recombinant pcrA binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. The pcrA protein can be labeled, such as by radioactivity or a colorimetric compound, such that the number of pcrA molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing pcrA-induced activities, thereby preventing the action of pcrA by excluding pcrA from binding.

Potential antagonists include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, J. Neurochem. 56: 560 (1991); OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton, Fla. (1988), for a description of these molecules). Preferred potential antagonists include compounds related to and variants of pcrA.

Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs. Additionally, the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgamo or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The invention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection. In particular the molecules of the invention may be used: in the prevention of adhesion of bacteria, in particular gram positive bacteria, to mammalian extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block pcrA protein-mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kinases (Rosenshine et al., Infect. Immun. 60:2211 (1992); to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial pcrA proteins that mediate tissue damage and; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.

The antagonists and agonists of the invention may be employed, for instance, to inhibit and treat otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid.

Vaccines

Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal which comprises inoculating the individual with pcrA, or a fragment or variant thereof, adequate to produce antibody and/or T cell immune response to protect said individual from infection, particularly bacterial infection and most particularly Streptococcus pneumoniae infection. Also provided are methods whereby such immunological response slows bacterial replication. Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector to direct expression of pcrA, or a fragment or a variant thereof, for expressing pcrA, or a fragment or a variant thereof in vivo in order to induce an immunological response, such as, to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not. One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise.

Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid.

A further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological response, induces an immunological response in such individual to a pcrA or protein coded therefrom, wherein the composition comprises a recombinant pcrA or protein coded therefrom comprising DNA which codes for and expresses an antigen of said pcrA or protein coded therefrom. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+T cells.

A pcrA polypeptide or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as lipoprotein D from Hemophilus influenzae, Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilize the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be attached to either the amino or carboxy terminus of the first protein.

Provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. et al. Science 273: 352 (1996).

Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of bacterial cell surface proteins in DNA constructs used in such genetic immunization experiments in animal models of infection with Streptococcus pneumoniae will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly Streptococcus pneumoniae infection, in mammals, particularly humans.

The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue. Examples of tissue damage include wounds in skin or connective tissue caused, e.g., by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagina.

The invention also includes a vaccine formulation which comprises an immunogenic recombinant protein of the invention together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

While the invention has been described with reference to certain pcrA protein, it is to be understood that this covers fragments of the naturally occurring protein and similar proteins with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant protein.

Compositions, kits and administration

The invention also relates to compositions comprising the polynucleotide or the polypeptides discussed above or their agonists or antagonists. The polypeptides of the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration. The invention further relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

Alternatively the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.

For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

In-dwelling devices include surgical implants, prosthetic devices and catheters, i.e., devices that are introduced to the body of an individual and remain in position for an extended time. Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospinal fluid shunts, urinary catheters, continuous ambulatory peritoneal dialysis (CAPD) catheters.

The composition of the invention may be administered by injection to achieve a systemic effect against relevant bacteria shortly before insertion of an in-dwelling device. Treatment may be continued after surgery during the in-body time of the device. In addition, the composition could also be used to broaden perioperative cover for any surgical technique to prevent bacterial wound infections, especially Streptococcus pneumoniae wound infections.

Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia. Late deep infection is a serious complication sometimes leading to loss of the prosthetic joint and is accompanied by significant morbidity and mortality. It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics in this situation.

In addition to the therapy described above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.

Alternatively, the composition of the invention may be used to bathe an indwelling device immediately before insertion. The active agent will preferably be present at a concentration of 1 μg/ml to 10 mg/ml for bathing of wounds or indwelling devices.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.

Each reference disclosed herein is incorporated by reference herein in its entirety. Any patent application to which this application claims priority is also incorporated by reference herein in its entirety.

EXAMPLES

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.

Example 1

Strain selection, Library Production and Sequencing

The polynucleotide having the DNA sequence given in SEQ ID NO: 1 was obtained from a library of clones of chromosomal DNA of Streptococcus pneumoniae in E. coli. The sequencing data from two or more clones containing overlapping Streptococcus pneumoniae DNAs was used to construct the contiguous DNA sequence in SEQ ID NO: 1. Libraries may be prepared by routine methods, for example:

Methods I and 2 below.

Total cellular DNA is isolated from Streptococcus pneumoniae 0100993 according to standard procedures and size-fractionated by either of two methods.

Method 1

Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate according to standard procedures. DNA fragments of up to 11 kbp in size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added. Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E. coli infected with the packaged library. The library is amplified by standard procedures.

Method 2

Total cellular DNA is partially hydrolyzed with a one or a combination of restriction enzymes appropriate to generate a series of fragments for cloning into library vectors (e.g., RsaI, PalI, AluI, Bshl235I), and such fragments are size-fractionated according to standard procedures. EcoRI linkers are ligated to the DNA and the fragments then ligated into the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E. coli infected with the packaged library. The library is amplified by standard procedures.

Example 2

pcrA Characterization

The staphylococcal gene may be essential for chromosome replication. Assays for activity include DNA unwinding assays.

    __________________________________________________________________________     #             SEQUENCE LISTING                                                    - -  - - (1) GENERAL INFORMATION:                                              - -    (iii) NUMBER OF SEQUENCES: 4                                            - -  - - (2) INFORMATION FOR SEQ ID NO:1:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 2292 base - #pairs                                                 (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: double                                                       (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                - - ATGAACGCAT TATTAAATGG AATGAATGAC CGTCAGGCTG AGGCGGTGCA AA -             #CGACAGAA     60                                                                  - - GGTCCCTTGC TAATCATGGC AGGGGCTGGT TCTGGAAAGA CTCGTGTTTT GA -             #CCCACCGT    120                                                                  - - ATCGCTTATT TGATTGATGA AAAGCTGGTC AATCTTTGGA TATTTTTGGC CA -             #TTACCTTT    180                                                                  - - ACCAACAAGG CTGCGCGTGA GATGAAAGAG CGTGCTTATA GCCTCAATCC AG -             #CGACTCAG    240                                                                  - - GACTGTCTGA TTGCGACCTT CCACTCCATG TGTGTGCGTA TTTTGCGTCG CG -             #ATGCGGAC    300                                                                  - - CATATTGGCT ACAATCGTAA TTTTACAATT GTGGATCCTG GTGAACAGCG AA -             #CGCTCATG    360                                                                  - - AAACGTATTC TCAAACAGTT GAACTTGGAC CCTAAAAAAT GGAATGAACG AA -             #CTATTTTG    420                                                                  - - GGGACCATTT CCAATGCTAA GAATGATTTG ATTGATGATG TTGCTTATGC TG -             #CCCAAGCT    480                                                                  - - GGCGATATGT ATACGCAAAT TGTGGCCCAG TGTTATACAG CCTATCAAAA AG -             #AACTTCGT    540                                                                  - - CAGTCTGAAT CCGTTGACTT TGATGATTTG ATTATGCTGA CCTTGCGTCT CT -             #TTGATCAA    600                                                                  - - AATCCTGATG TTTTGACCTA CTACCAGCAA AAATTCCAAT ACATCCACGT TG -             #ATGAGTAC    660                                                                  - - CAAGATACCA ACCACGCTCA GTACCAATTG GTCAAACTCT TGGCTTCCCG TT -             #TTAAAAAT    720                                                                  - - ATCTGTGTGG TTGGGGATGC GGACCAGTCT ATCTACGGTT GGCGTGGTGC TG -             #ATATGCAG    780                                                                  - - AATATCTTGG ACTTTGAAAA GGATTACCCC AAAGCCAAGG TTGTTTTGTT GG -             #AGGAAAAT    840                                                                  - - TACCGCTCAA CCAAAACCAT TCTCCAAGCG GCCAACGAGG TTATTAAAAA TA -             #ATAAAAAT    900                                                                  - - CGCCGTCCTA AAAATCTCTG GACTCAAAAC GCTGATGGGG AGCAAATCGT TT -             #ACTATCGT    960                                                                  - - GCCGATGATG AGCTGGATGA GGCTGTATTT GTAGCCAGAA CCATCGATGA AC -             #TTAGTCGC   1020                                                                  - - AGTCAAAACT TCCTTCATAA GGATTTTGCA GTTCTCTATC GGACTAATGC CC -             #AGTCCCGT   1080                                                                  - - ACAATTGAGG AAGCCCTGCT CAAGTCTAAC ATTCCTTATA CCATGGTTGG CG -             #GAACCAAA   1140                                                                  - - TTCTACAGCC GTAAGGAAAT TCGCGATATT ATTGCTTATC TCATCTTTAT TG -             #CTAATTTG   1200                                                                  - - AGTGACAATA TTAGTTTTGA GCGTATTATC AACGAGCCTA AACGTGGAAT TG -             #GTCTAGGT   1260                                                                  - - ACAGTTGAGA AAATCCGTGA TTTTGCAAAT TTGCAAAATA TGTCTATGCT GG -             #ATGCTTCT   1320                                                                  - - GCTAATATTA TGTTGTCTGG TATCAAGGGT AAGGCAGCCC AATCTATCTG GG -             #ATTTTGCC   1380                                                                  - - AATATGATGC TTGATTTGCG GGAGCAGCTA GACCACTTAA GCATTACAGA GT -             #TGGTTGAG   1440                                                                  - - TCCGTCCTAG AAAAAACAGG TTATGTCGAT ATTCTTAACG CCCAAGCGAC TC -             #TAGAAAGC   1500                                                                  - - AAGGCACGGG TTGAAAATAT CGAAGAGTTT CTTTCTGTTA CGAAGAACTT TG -             #ATGACACC   1560                                                                  - - ACGGATGTGA CAGAAGAGGA AACTGGTCTG GACAAACTGA GTCGTTTCTT AA -             #ATGACTTG   1620                                                                  - - GCTTTGATTG CCGACACAGA TTCAGGTAGT CAGGAGACAT CAGAAGTGAC CT -             #TGATGACC   1680                                                                  - - CTGCATGCTG CCAAAGGTCT CGAATTTCCA GTTGTCTTTT TGATTGGGAT GG -             #AAGAAAAT   1740                                                                  - - GTCTTTCCAC TTAGTCGTGC GACTGAAGAT TCAGATGAAT TAGAAGAAGA GC -             #GCCGTCTA   1800                                                                  - - GCCTATGTAG GTATCACGCG TGCAGAGAAA ATTCTCTATC TGACCAATGC CA -             #ACTCACGC   1860                                                                  - - TTGCTTTTTG GTCGTACCAA TTATAACCGT CCGACTCGTT TTATTAACGA AA -             #TCAGTTCA   1920                                                                  - - GACTTGCTTG AGTATCAAGG TCTGGCTCGT CCTGCAAATA CAAGCTTTAA GG -             #CATCATAT   1980                                                                  - - AGCAGTGGTA GTATTTCCTT TGGTCAAGGT ATGAGTTTGG CTCAGGCTCT TC -             #AAGACCGT   2040                                                                  - - AAACGCGGTG CTGCCCCAAA ATCAATCCAG TCAAGCGGTC TTCCATTTGG TC -             #AATTTACA   2100                                                                  - - GCTGGCGCAA AACCAGCATC TAGCGAGGCA AATTGGTCCA TTGGTGATAT TG -             #CTCTCCAC   2160                                                                  - - AAGAAATGGG GAGAGGGAAC CGTTCTGGAA GTTTCAGGTA GCGGTGCTAG GC -             #AGGAATTG   2220                                                                  - - AAAATCAATT TCCCAGAAGT AGGTTTGAAA AAACTTTTAG CCAGTGTGGC TC -             #CAATTGAG   2280                                                                  - - AAAAAAATCT AA              - #                  - #                       - #     2292                                                                   - -  - - (2) INFORMATION FOR SEQ ID NO:2:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 763 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                - - Met Asn Ala Leu Leu Asn Gly Met Asn Asp Ar - #g Gln Ala Glu Ala Val        1               5  - #                10  - #                15                - - Gln Thr Thr Glu Gly Pro Leu Leu Ile Met Al - #a Gly Ala Gly Ser Gly                   20      - #            25      - #            30                    - - Lys Thr Arg Val Leu Thr His Arg Ile Ala Ty - #r Leu Ile Asp Glu Lys               35          - #        40          - #        45                        - - Leu Val Asn Leu Trp Ile Phe Leu Ala Ile Th - #r Phe Thr Asn Lys Ala           50              - #    55              - #    60                            - - Ala Arg Glu Met Lys Glu Arg Ala Tyr Ser Le - #u Asn Pro Ala Thr Gln       65                  - #70                  - #75                  - #80         - - Asp Cys Leu Ile Ala Thr Phe His Ser Met Cy - #s Val Arg Ile Leu Arg                       85  - #                90  - #                95                - - Arg Asp Ala Asp His Ile Gly Tyr Asn Arg As - #n Phe Thr Ile Val Asp                   100      - #           105      - #           110                   - - Pro Gly Glu Gln Arg Thr Leu Met Lys Arg Il - #e Leu Lys Gln Leu Asn               115          - #       120          - #       125                       - - Leu Asp Pro Lys Lys Trp Asn Glu Arg Thr Il - #e Leu Gly Thr Ile Ser           130              - #   135              - #   140                           - - Asn Ala Lys Asn Asp Leu Ile Asp Asp Val Al - #a Tyr Ala Ala Gln Ala       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Gly Asp Met Tyr Thr Gln Ile Val Ala Gln Cy - #s Tyr Thr Ala Tyr         Gln                                                                                              165  - #               170  - #               175              - - Lys Glu Leu Arg Gln Ser Glu Ser Val Asp Ph - #e Asp Asp Leu Ile Met                   180      - #           185      - #           190                   - - Leu Thr Leu Arg Leu Phe Asp Gln Asn Pro As - #p Val Leu Thr Tyr Tyr               195          - #       200          - #       205                       - - Gln Gln Lys Phe Gln Tyr Ile His Val Asp Gl - #u Tyr Gln Asp Thr Asn           210              - #   215              - #   220                           - - His Ala Gln Tyr Gln Leu Val Lys Leu Leu Al - #a Ser Arg Phe Lys Asn       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Ile Cys Val Val Gly Asp Ala Asp Gln Ser Il - #e Tyr Gly Trp Arg         Gly                                                                                              245  - #               250  - #               255              - - Ala Asp Met Gln Asn Ile Leu Asp Phe Glu Ly - #s Asp Tyr Pro Lys Ala                   260      - #           265      - #           270                   - - Lys Val Val Leu Leu Glu Glu Asn Tyr Arg Se - #r Thr Lys Thr Ile Leu               275          - #       280          - #       285                       - - Gln Ala Ala Asn Glu Val Ile Lys Asn Asn Ly - #s Asn Arg Arg Pro Lys           290              - #   295              - #   300                           - - Asn Leu Trp Thr Gln Asn Ala Asp Gly Glu Gl - #n Ile Val Tyr Tyr Arg       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Ala Asp Asp Glu Leu Asp Glu Ala Val Phe Va - #l Ala Arg Thr Ile         Asp                                                                                              325  - #               330  - #               335              - - Glu Leu Ser Arg Ser Gln Asn Phe Leu His Ly - #s Asp Phe Ala Val Leu                   340      - #           345      - #           350                   - - Tyr Arg Thr Asn Ala Gln Ser Arg Thr Ile Gl - #u Glu Ala Leu Leu Lys               355          - #       360          - #       365                       - - Ser Asn Ile Pro Tyr Thr Met Val Gly Gly Th - #r Lys Phe Tyr Ser Arg           370              - #   375              - #   380                           - - Lys Glu Ile Arg Asp Ile Ile Ala Tyr Leu Il - #e Phe Ile Ala Asn Leu       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - Ser Asp Asn Ile Ser Phe Glu Arg Ile Ile As - #n Glu Pro Lys Arg         Gly                                                                                              405  - #               410  - #               415              - - Ile Gly Leu Gly Thr Val Glu Lys Ile Arg As - #p Phe Ala Asn Leu Gln                   420      - #           425      - #           430                   - - Asn Met Ser Met Leu Asp Ala Ser Ala Asn Il - #e Met Leu Ser Gly Ile               435          - #       440          - #       445                       - - Lys Gly Lys Ala Ala Gln Ser Ile Trp Asp Ph - #e Ala Asn Met Met Leu           450              - #   455              - #   460                           - - Asp Leu Arg Glu Gln Leu Asp His Leu Ser Il - #e Thr Glu Leu Val Glu       465                 4 - #70                 4 - #75                 4 -       #80                                                                               - - Ser Val Leu Glu Lys Thr Gly Tyr Val Asp Il - #e Leu Asn Ala Gln         Ala                                                                                              485  - #               490  - #               495              - - Thr Leu Glu Ser Lys Ala Arg Val Glu Asn Il - #e Glu Glu Phe Leu Ser                   500      - #           505      - #           510                   - - Val Thr Lys Asn Phe Asp Asp Thr Thr Asp Va - #l Thr Glu Glu Glu Thr               515          - #       520          - #       525                       - - Gly Leu Asp Lys Leu Ser Arg Phe Leu Asn As - #p Leu Ala Leu Ile Ala           530              - #   535              - #   540                           - - Asp Thr Asp Ser Gly Ser Gln Glu Thr Ser Gl - #u Val Thr Leu Met Thr       545                 5 - #50                 5 - #55                 5 -       #60                                                                               - - Leu His Ala Ala Lys Gly Leu Glu Phe Pro Va - #l Val Phe Leu Ile         Gly                                                                                              565  - #               570  - #               575              - - Met Glu Glu Asn Val Phe Pro Leu Ser Arg Al - #a Thr Glu Asp Ser Asp                   580      - #           585      - #           590                   - - Glu Leu Glu Glu Glu Arg Arg Leu Ala Tyr Va - #l Gly Ile Thr Arg Ala               595          - #       600          - #       605                       - - Glu Lys Ile Leu Tyr Leu Thr Asn Ala Asn Se - #r Arg Leu Leu Phe Gly           610              - #   615              - #   620                           - - Arg Thr Asn Tyr Asn Arg Pro Thr Arg Phe Il - #e Asn Glu Ile Ser Ser       625                 6 - #30                 6 - #35                 6 -       #40                                                                               - - Asp Leu Leu Glu Tyr Gln Gly Leu Ala Arg Pr - #o Ala Asn Thr Ser         Phe                                                                                              645  - #               650  - #               655              - - Lys Ala Ser Tyr Ser Ser Gly Ser Ile Ser Ph - #e Gly Gln Gly Met Ser                   660      - #           665      - #           670                   - - Leu Ala Gln Ala Leu Gln Asp Arg Lys Arg Gl - #y Ala Ala Pro Lys Ser               675          - #       680          - #       685                       - - Ile Gln Ser Ser Gly Leu Pro Phe Gly Gln Ph - #e Thr Ala Gly Ala Lys           690              - #   695              - #   700                           - - Pro Ala Ser Ser Glu Ala Asn Trp Ser Ile Gl - #y Asp Ile Ala Leu His       705                 7 - #10                 7 - #15                 7 -       #20                                                                               - - Lys Lys Trp Gly Glu Gly Thr Val Leu Glu Va - #l Ser Gly Ser Gly         Ala                                                                                              725  - #               730  - #               735              - - Arg Gln Glu Leu Lys Ile Asn Phe Pro Glu Va - #l Gly Leu Lys Lys Leu                   740      - #           745      - #           750                   - - Leu Ala Ser Val Ala Pro Ile Glu Lys Lys Il - #e                                   755          - #       760                                              - -  - - (2) INFORMATION FOR SEQ ID NO:3:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 1584 base - #pairs                                                 (B) TYPE: nucleic acid                                                         (C) STRANDEDNESS: double                                                       (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                - - CTACAACTCT TGGTTACTAA GCGCTTCAAC TCCTTCCTTG GCCAGCCTTT CT -              #CTTGGTAA     60                                                                  - - TAGTGAATCT TCTTGGAATG AAATACTGTA CATAAAAATC CTCCTCACTT TA -             #TTATTCGT    120                                                                  - - GAGAAGGATG GAAAATTAGA TTTTTTTCTC AATTGGAGCC ACACTGGCTA AA -             #AGTTTTTT    180                                                                  - - CAAACCTACT TCTGGGAAAT TGATTTTCAA TTCCTGCCTA GCACCGCTAC CT -             #GAAACTTC    240                                                                  - - CAGAACGGTT CCCTCTCCCC ATTTCTTGTG GAGAGCAATA TCACCAATGG AC -             #CAATTTGC    300                                                                  - - CTCGCTAGAT GCTGGTTTTG CGCCAGCTGT AAATTGACCA AATGGAAGAC CG -             #CTTGACTG    360                                                                  - - GATTGATTTT GGGGCAGCAC CGCGTTTACG GTCTTGAAGA GCCTGAGCCA AA -             #CTCATACC    420                                                                  - - TTGACCAAAG GAAATACTAC CACTGCTATA TGATGCCTTA AAGCTTGTAT TT -             #GCAGGACG    480                                                                  - - AGCCAGACCT TGATACTCAA GCAAGTCTGA ACTGATTTCG TTAATAAAAC GA -             #GTCGGACG    540                                                                  - - GTTATAATTG GTACGACCAA AAAGCAAGCG TGAGTTGGCA TTGGTCAGAT AG -             #AGAATTTT    600                                                                  - - CTCTGCACGC GTGATACCTA CATAGGCTAG ACGGCGCTCT TCTTCTAATT CA -             #TCTGAATC    660                                                                  - - TTCAGTCGCA CGACTAAGTG GAAAGACATT TTCTTCCATC CCAATCAAAA AG -             #ACAACTGG    720                                                                  - - AAATTCGAGA CCTTTGGCAG CATGCAGGGT CATCAAGGTC ACTTCTGATG TC -             #TCCTGACT    780                                                                  - - ACCTGAATCT GTGTCGGCAA TCAAAGCCAA GTCATTTAAG AAACGACTCA GT -             #TTGTCCAG    840                                                                  - - ACCAGTTTCC TCTTCTGTCA CATCCGTGGT GTCATCAAAG TTCTTCGTAA CA -             #GAAAGAAA    900                                                                  - - CTCTTCGATA TTTTCAACCC GTGCCTTGCT TTCTAGAGTC GCTTGGGCGT TA -             #AGAATATC    960                                                                  - - GACATAACCT GTTTTTTCTA GGACGGACTC AACCAACTCT GTAATGCTTA AG -             #TGGTCTAG   1020                                                                  - - CTGCTCCCGC AAATCAAGCA TCATATTGGC AAAATCCCAG ATAGATTGGG CT -             #GCCTTACC   1080                                                                  - - CTTGATACCA GACAACATAA TATTAGCAGA AGCATCCAGC ATAGACATAT TT -             #TGCAAATT   1140                                                                  - - TGCAAAATCA CGGATTTTCT CAACTGTACC TAGACCAATT CCACGTTTAG GC -             #TCGTTGAT   1200                                                                  - - AATACGCTCA AAACTAATAT TGTCACTCAA ATTAGCAATA AGGTTGAGAT AA -             #GCAATAAT   1260                                                                  - - ATCGCGAATT TCCTTACGGC TGTAGAATTT GGTTCCGCCA ACCATGGTAT AA -             #GGAATGTT   1320                                                                  - - AGACTTGAGC AGGGCTTCAT CGAATTGTAC GGGACTGGGC ATTAGTCCGA TA -             #GAGAACTG   1380                                                                  - - CAAAATCCTT ATGAAGGAAG TTTTGACTGC GACTAAGTTC ATCGATGGTT CT -             #GGCTACAA   1440                                                                  - - ATACAGCCTC ATCCAGCTCA TCATCGGCAC GATAGTAAAC GATTTGCTCC CC -             #ATCAGCGT   1500                                                                  - - TTTGAGTCCA GAGATTTTTA GGACGGCGAT TTTTATTATT TTTAATAACC TC -             #GTTGGCCG   1560                                                                  - - CTTGGAGAAT GGTTTTGGTT GAGC          - #                  - #                   1584                                                                      - -  - - (2) INFORMATION FOR SEQ ID NO:4:                                      - -      (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 428 amino - #acids                                                 (B) TYPE: amino acid                                                           (C) STRANDEDNESS: single                                                       (D) TOPOLOGY: linear                                                  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                                - - Met Asn Leu Val Ala Val Lys Thr Ser Phe Il - #e Arg Ile Leu Gln Phe        1               5  - #                10  - #                15                - - Ser Ile Gly Leu Met Pro Ser Pro Val Gln Ph - #e Asp Glu Ala Leu Leu                   20      - #            25      - #            30                    - - Lys Ser Asn Ile Pro Tyr Thr Met Val Gly Gl - #y Thr Lys Phe Tyr Ser               35          - #        40          - #        45                        - - Arg Lys Glu Ile Arg Asp Ile Ile Ala Tyr Le - #u Asn Leu Ile Ala Asn           50              - #    55              - #    60                            - - Leu Ser Asp Asn Ile Ser Phe Glu Arg Ile Il - #e Asn Glu Pro Lys Arg       65                  - #70                  - #75                  - #80         - - Gly Ile Gly Leu Gly Thr Val Glu Lys Ile Ar - #g Asp Phe Ala Asn Leu                       85  - #                90  - #                95                - - Gln Asn Met Ser Met Leu Asp Ala Ser Ala As - #n Ile Met Leu Ser Gly                   100      - #           105      - #           110                   - - Ile Lys Gly Lys Ala Ala Gln Ser Ile Trp As - #p Phe Ala Asn Met Met               115          - #       120          - #       125                       - - Leu Asp Leu Arg Glu Gln Leu Asp His Leu Se - #r Ile Thr Glu Leu Val           130              - #   135              - #   140                           - - Glu Ser Val Leu Glu Lys Thr Gly Tyr Val As - #p Ile Leu Asn Ala Gln       145                 1 - #50                 1 - #55                 1 -       #60                                                                               - - Ala Thr Leu Glu Ser Lys Ala Arg Val Glu As - #n Ile Glu Glu Phe         Leu                                                                                              165  - #               170  - #               175              - - Ser Val Thr Lys Asn Phe Asp Asp Thr Thr As - #p Val Thr Glu Glu Glu                   180      - #           185      - #           190                   - - Thr Gly Leu Asp Lys Leu Ser Arg Phe Leu As - #n Asp Leu Ala Leu Ile               195          - #       200          - #       205                       - - Ala Asp Thr Asp Ser Gly Ser Gln Glu Thr Se - #r Glu Val Thr Leu Met           210              - #   215              - #   220                           - - Thr Leu His Ala Ala Lys Gly Leu Glu Phe Pr - #o Val Val Phe Leu Ile       225                 2 - #30                 2 - #35                 2 -       #40                                                                               - - Gly Met Glu Glu Asn Val Phe Pro Leu Ser Ar - #g Ala Thr Glu Asp         Ser                                                                                              245  - #               250  - #               255              - - Asp Glu Leu Glu Glu Glu Arg Arg Leu Ala Ty - #r Val Gly Ile Thr Arg                   260      - #           265      - #           270                   - - Ala Glu Lys Ile Leu Tyr Leu Thr Asn Ala As - #n Ser Arg Leu Leu Phe               275          - #       280          - #       285                       - - Gly Arg Thr Asn Tyr Asn Arg Pro Thr Arg Ph - #e Ile Asn Glu Ile Ser           290              - #   295              - #   300                           - - Ser Asp Leu Leu Glu Tyr Gln Gly Leu Ala Ar - #g Pro Ala Asn Thr Ser       305                 3 - #10                 3 - #15                 3 -       #20                                                                               - - Phe Lys Ala Ser Tyr Ser Ser Gly Ser Ile Se - #r Phe Gly Gln Gly         Met                                                                                              325  - #               330  - #               335              - - Ser Leu Ala Gln Ala Leu Gln Asp Arg Lys Ar - #g Gly Ala Ala Pro Lys                   340      - #           345      - #           350                   - - Ser Ile Gln Ser Ser Gly Leu Pro Phe Gly Gl - #n Phe Thr Ala Gly Ala               355          - #       360          - #       365                       - - Lys Pro Ala Ser Ser Glu Ala Asn Trp Ser Il - #e Gly Asp Ile Ala Leu           370              - #   375              - #   380                           - - His Lys Lys Trp Gly Glu Gly Thr Val Leu Gl - #u Val Ser Gly Ser Gly       385                 3 - #90                 3 - #95                 4 -       #00                                                                               - - Ala Arg Gln Glu Leu Lys Ile Asn Phe Pro Gl - #u Val Gly Leu Lys         Lys                                                                                              405  - #               410  - #               415              - - Leu Leu Ala Ser Val Ala Pro Ile Glu Lys Ly - #s Ile                                   420      - #           425                                        __________________________________________________________________________ 

What is claimed is:
 1. An isolated protein comprising a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:2.
 2. A composition comprising the isolated protein of claim 1 and a pharmaceutically acceptable carrier.
 3. An isolated fusion protein comprising a heterologous amino acid sequence fused to the amino acid sequence set forth in SEQ ID NO:2.
 4. A composition comprising the isolated fusion protein of claim 3 and a pharmaceutically acceptable carrier.
 5. The isolated protein of claim 1, wherein the isolated protein consists of the amino acid sequence set forth in SEQ ID NO:2.
 6. A composition comprising the isolated protein of claim 5 and a pharmaceutically acceptable carrier.
 7. An isolated protein comprising a polypeptide comprising at least 50 consecutive amino acids of SEQ ID NO:2.
 8. A composition comprising the isolated protein of claim 7 and a pharmaceutically acceptable carrier.
 9. An isolated fusion protein comprising a heterologous amino acid sequence fused to the polypeptide of claim
 7. 10. A composition comprising the isolated fusion protein of claim 9 and a pharmaceutically acceptable carrier.
 11. The isolated protein of claim 7, wherein the isolated protein consists of 50 consecutive amino acids of SEQ ID NO:2.
 12. A composition comprising the isolated protein of claim 11 and a pharmaceutically acceptable carrier.
 13. An isolated protein comprising a polypeptide comprising at least 30 consecutive amino acids of SEQ ID NO:2.
 14. A composition comprising the isolated protein of claim 13 and a pharmaceutically acceptable carrier.
 15. An isolated fusion protein comprising a heterologous amino acid sequence fused to the polypeptide of claim
 13. 16. A composition comprising the isolated fusion protein of claim 15 and a pharmaceutically acceptable carrier.
 17. The isolated protein of claim 14, wherein the isolated protein consists of 30 consecutive amino acids of SEQ ID NO:2.
 18. A composition comprising the isolated protein of claim 17 and a pharmaceutically acceptable carrier. 